Department of Traditional Chinese Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Xuhui District, No.600 Yi Shan Road, Shanghai, 200233, China.
Second Clinical Medicine College, Heilongjiang University of Chinese Medicine, Harbin, 150040, China.
Neurotox Res. 2023 Feb;41(1):41-56. doi: 10.1007/s12640-022-00626-z. Epub 2023 Jan 3.
Alzheimer's disease (Alzheimer's disease, AD) is a neurodegenerative disease characterized by senile plaque deposition and neurofibrillary tangles. The pathogenesis of AD is complicated and the drugs used to treat AD are single-targeted drugs, which can only improve or alleviate the symptoms of patients, but cannot delay or prevent the progress of the disease. Because of its ability to act on multiple targets, multiple systems, multiple links, and multiple pathways, Chinese herbal compound prescriptions have shown unique advantages in the research and treatment of AD. Our previous study has demonstrated the protect role of the Chinese medicine Rehmannia in AD. However, the underlying mechanism remains unclear. In the present study, both in vitro and vivo experiments were employed, and we found Catalpol (Ca), the main extract of Rehmannia, could mitigate AD progression both in vitro and in vivo by promoting miR-138-5p level in neural stem cell secreted exosomes.
阿尔茨海默病（Alzheimer's disease，AD）是一种以老年斑沉积和神经纤维缠结为特征的神经退行性疾病。AD 的发病机制复杂，用于治疗 AD 的药物为单靶点药物，只能改善或缓解患者的症状，不能延缓或阻止疾病的进展。由于中草药复方制剂具有多靶点、多系统、多环节、多途径的作用特点，在 AD 的研究和治疗中显示出独特的优势。我们之前的研究表明中药地黄在 AD 中的保护作用。然而，其潜在的机制尚不清楚。在本研究中，我们通过体外和体内实验发现，地黄的主要提取物梓醇（Ca）可以通过促进神经干细胞分泌的外泌体中 miR-138-5p 的水平，在体外和体内减轻 AD 的进展。
